1. Home
  2. GSIW vs EVAX Comparison

GSIW vs EVAX Comparison

Compare GSIW & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

HOLD

Current Price

$14.30

Market Cap

24.2M

Sector

N/A

ML Signal

HOLD

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.07

Market Cap

29.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
EVAX
Founded
2016
2008
Country
Hong Kong
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
29.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
GSIW
EVAX
Price
$14.30
$3.07
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
48.3K
229.8K
Earning Date
08-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$2.77
52 Week High
$38.55
$12.15

Technical Indicators

Market Signals
Indicator
GSIW
EVAX
Relative Strength Index (RSI) 34.99 49.98
Support Level $0.11 $2.91
Resistance Level $18.03 $3.62
Average True Range (ATR) 1.83 0.15
MACD 0.14 0.00
Stochastic Oscillator 27.70 35.38

Price Performance

Historical Comparison
GSIW
EVAX

About GSIW Garden Stage Limited

Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: